Adenocarcinoma Ex-Goblet Cell: a Retrospective Experience.
PURPOSE
Adenocarcinoma ex-goblet cell carcinoids (AGCCs) are rare appendiceal tumors with mixed neuroendocrine and glandular features. They tend to behave more aggressively than typical carcinoid tumors, affect younger patients, and have a greater predilection for spreading to the peritoneum. Outcomes of AGCC patients treated with chemotherapy, extrapolated from colon cancer regimens, in the adjuvant or metastatic setting have not been explicitly reported. We sought to explore outcomes of AGCC patients with either local disease treated with adjuvant FOLFOX or metastatic disease treated with FOLFOX/FOLFIRI post-cytoreductive debulking (or CRS plus HIPEC in the peritoneal-limited setting).


METHODS
We performed a single-institution retrospective analysis of 23 pathologically identified AGCC patients from Vanderbilt University Medical Center treated with chemotherapy in either the adjuvant or metastatic settings. Each patient's tumor was categorized as group B or group C based on the criteria from Tang et al. Median progression-free survival (PFS) or disease-free survival (DFS) (in the curative setting) and overall survival (OS) were determined for each patient and specified patient subgroup.


RESULTS AND CONCLUSION
AGCC patients who were treated with FOLFOX chemotherapy in the adjuvant setting or FOLFOX/FOLFIRI in the metastatic setting experienced prolonged PFS, DFS, and OS. Five patients with peritoneal-limited disease treated with CRS plus HIPEC have not yet reached median PFS or OS. While small sample size, patient selection, and retrospective nature limit the generalizability of findings from our analysis, the efficacy signals we observed suggest prospective evaluation with chemotherapy and CRS plus HIPEC is warranted in AGCC patients.
['Das|Satya|S|', 'Shi|Chanjuan|C|', 'Du|Liping|L|', 'Idrees|Kamran|K|', 'Berlin|Jordan|J|']
D000971:Antineoplastic Combined Chemotherapy Protocols D001063:Appendiceal Neoplasms D002166:Camptothecin D002276:Carcinoid Tumor D017024:Chemotherapy, Adjuvant D065426:Cytoreduction Surgical Procedures D018572:Disease-Free Survival D005260:Female D005472:Fluorouracil D005500:Follow-Up Studies D020397:Goblet Cells D006801:Humans D006979:Hyperthermia, Induced D002955:Leucovorin D008297:Male D008875:Middle Aged D009944:Organoplatinum Compounds D010534:Peritoneal Neoplasms D000077982:Progression-Free Survival D012189:Retrospective Studies
Adenocarcinoma ex-goblet cell Appendiceal tumor Chemotherapy HIPEC